XML 36 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Operations (Unaudited) (USD $)
 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Revenues:        
License fee and milestone revenue $ 22,495 $ 76,888 $ 68,240 $ 129,712
License fee and milestone revenue from affiliated entity 106,250 106,250 318,750 305,208
Revenue under collaborative research and development arrangements with affiliated entity 116,234   116,234  
Grant and miscellaneous revenue 609,717 2,454,423 2,480,675 7,727,669
Total revenues 854,696 2,637,561 2,983,899 8,162,589
Operating expenses:        
Research and development 4,972,319 6,987,824 13,541,984 15,873,601
General and administrative 2,674,362 2,323,188 7,859,359 8,734,806
Gain on sale of assets (500,000) (337,000) (1,151,000) (587,000)
Total operating expenses 7,146,681 8,974,012 20,250,343 24,021,407
Loss from operations (6,291,985) (6,336,451) (17,266,444) (15,858,818)
Other income (expense):        
Interest and other income, net 37,013 5,738 109,593 15,392
Change in fair value of common stock warrants (1,113,638) 346,956 (1,067,029) 7,577,582
Gain (Loss) from investment in affiliated entity 736,121 1,427,176 (817,796) (1,550,062)
Net loss (6,632,489) (4,556,581) (19,041,676) (9,815,906)
Net loss attributable to non-controlling interest 10,413 14,649 31,472 39,202
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (6,622,076) $ (4,541,932) $ (19,010,204) $ (9,776,704)
Loss per common share - basic and diluted:        
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders $ (0.05) $ (0.04) $ (0.14) $ (0.08)
Weighted average number of common shares outstanding - basic and diluted 135,389,308 127,256,907 135,108,699 125,184,087